Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $36.9400 (-0.58%) ($36.9400 - $36.9400) on Fri. Jul. 16, 2021. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 2.9% (three month average) | RSI | 41 | Latest Price | $36.9400(-0.58%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -1.7% a day on average for past five trading days. | Weekly Trend | TGTX declines -1.9% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(68%) ARKG(63%) ARKK(59%) IWO(59%) IBB(58%) | Factors Impacting TGTX price | TGTX will decline at least -1.45% in a week (0% probabilities). VIXM(-45%) VXX(-38%) UUP(-19%) UNG(-3%) TLT(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.45% (StdDev 2.9%) | Hourly BBV | -0.5 () | Intraday Trend | 0% | | | |
|
Resistance Level | $38.5 | 5 Day Moving Average | $37.83(-2.35%) | 10 Day Moving Average | $38.41(-3.83%) | 20 Day Moving Average | $38.5(-4.05%) | To recent high | -17.7% | To recent low | 13.9% | Market Cap | $4.678b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |